Enforcement Litigation and Compliance Washington , DC December 9-10, 2015 Compliance Central with FDA Center Compliance Directors (Part II) Mary Malarkey, Director, Office of Compliance and Biologics Quality, CBER Cynthia Schnedar, Director, Office of Compliance, CDER CAPT Sean Boyd, Acting Director, Office of Compliance, CDRH Moderated by John Taylor, Principal Compliance and Regulatory Affairs, Greenleaf Health LLC, and Member, FDLI Board
67
Embed
Enforcement Litigation and Compliance Washington, DC December 9- 10, 2015 Compliance Central with FDA Center Compliance Directors (Part II) Mary Malarkey,
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Enforcement Litigation and Compliance
Washington, DC
December 9-10, 2015
Compliance Central with FDA Center Compliance Directors (Part II)
Mary Malarkey, Director, Office of Compliance and Biologics Quality, CBER
Cynthia Schnedar, Director, Office of Compliance, CDER
CAPT Sean Boyd, Acting Director, Office of Compliance, CDRH
Moderated by John Taylor, Principal Compliance and Regulatory Affairs, Greenleaf Health LLC, and Member, FDLI Board
Compliance Central with FDA Center Compliance Directors (Part II)
Mary Malarkey, Director, Office of Compliance and Biologics Quality, CBER
Cynthia Schnedar, Director, Office of Compliance, CDER
Sean Boyd, Acting Director, Office of Compliance, CDRH
Moderated by John Taylor, Principal Compliance and Regulatory Affairs, Greenleaf
Health LLC, and Member, FDLI Board
CBER Compliance UpdateFDLI Enforcement, Litigation and Compliance
ConferenceDecember 9, 2015
Mary Malarkey, DirectorOffice of Compliance and Biologics Quality
Center for Biologics Evaluation and Research/FDA
Office of Compliance and Biologics Quality
4
OCBQ’s mission is to ensure the quality of products regulated by CBER over their
entire lifecycle through pre-market review and inspection, and post-market review, surveillance, inspection, outreach and
compliance
5
Rules and Guidance: Update
6
Drug Shortages: Final Rule
• “Permanent Discontinuance or Interruption in Manufacturing of Certain Drug or Biological Products.” 7/8/2015
• Effective date: September 8, 2015• Requirements for electronic notification of FDA of
a “permanent discontinuance or an interruption in manufacturing of the product that is likely to lead to a meaningful disruption in supply (or a significant disruption in supply for blood or blood components) of the product in the United States.”
7
21 CFR 600.82
• Adds biological drugs to requirements in 506(c) of the Federal Food Drug and Cosmetic Act and amends the regulations
• All applicants with an approved BLA for a covered biological product, other than blood or blood components (§ 600.82(a)(1)).
• Applicants with an approved BLA for blood or blood components, if the applicant is a manufacturer of a significant percentage of the U.S. blood supply (§ 600.82(a)(2)).
8
General Safety Test: Final Rule
• “Revocation of General Safety Test Regulations That Are Duplicative of Requirements in Biologics License Applications,” effective date August 3, 2015.
• “For a number of years, FDA has not codified specific test methods as standards for licensed biological products, in part because codifying specific test methods as standards can diminish the ability of the Agency and industry to respond to technological developments.”
9
GST - 2
• “The final rule is removing Sec. Sec. 610.11, 610.11a, and 680.3(b), the regulations that require that manufacturers of biological products perform a specified test for general safety of biological products. FDA is taking this action because the existing codified GST regulations are duplicative, outmoded, or are otherwise unnecessary to help ensure the continued safety, purity, and potency of licensed biological products.”
10
Draft “Guidance for Industry:Request for Quality Metrics”
• Draft guidance issued on July 27, 2015• Public meeting held August 24, 2015;
questions to stakeholders in the Notice of Availability for the guidance.
• FDA extended comment period to November 27, 2015.
11
Applicability to Biologics?
• Scope:– Exemptions include manufacturers of blood
and blood components for transfusion, vaccines, cell therapy products, gene therapy products, allergenic extracts, human cells, tissues, and cellular and tissue based products and non-recombinant versions of plasma derived products.
12
Draft Guidance Compounding
• “Mixing, Diluting or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application,” February 13, 2015. Comment period until May 20, 2015.
• “This draft guidance describes the conditions under which FDA does not intend to take action against a state-licensed pharmacy, a Federal facility, or outsourcing facility that mixes, dilutes, or repackages certain biological products without obtaining an approved biologics license application (BLA).”
13
Recent HCT/P Draft Guidance Documents
• Provides FDA’s current thinking on certain criteria in 21 CFR 1271.10(a) and the exception in 1271.15(b).
• Industry uses these regulations to determine the need for FDA premarket review and approval
• Alternatively, the Tissue Reference Group and/or submission of a Request for Designation provide informal and formal avenues for FDA input.
14
Exception based on the consideration that autologous cells or tissues removed from an individual and implanted into the same individual without intervening processing beyond rinsing, cleansing, or sizing, or certain manufacturing steps, raise no additional risks of contamination and communicable disease transmission beyond that typically associated with surgery.
Explains the regulation and its three parts:•Autologous use•Removed and implanted in same procedure
• Two procedures consisting of more than a single operation are listed – craniectomy , parathyroidectomy
•Remain “such HCT/Ps”
Same surgical procedure exception
Based on the bipartite regulatory definition of ‘minimal manipulation’•For structural tissue, minimal manipulation means that the processing does not alter the original relevant characteristics of the tissue relating to the tissue’s utility for reconstruction, repair, or replacement.•For cells or nonstructural tissue, minimal manipulation means that the processing does not alter the relevant biological characteristics of the cells or tissues.
The draft guidance explains•How to determine whether an HCT/P is a structural tissue or a cellular/nonstructural tissue for the purpose of applying the definition•How to determine if it is minimally manipulated
Minimal Manipulation
This draft guidance responds to the numerous inquiries regarding HCT/Ps manufactured from adipose tissues.
It explains•How the four criteria in 1271.10(a) apply to adipose tissue-derived products•How to determine whether adipose tissue that is implanted into the same individual during the same surgical procedure is subject to FDA regulation•How to get more information about the appropriate regulatory considerations
Autologous adipose tissue
Homologous Use
Homologous use is defined as: The repair, reconstruction, replacement, or supplementation of a recipient’s cells or tissues with an HCT/P that performs the same basic function or functions in the recipient as in the donor (21 CFR 1271.3(c)).
The draft guidance explains:•Key terms•Recommendations for applying the homologous use criterion; provides examples
• With ORA, working through commitments in FY2015 Biologics Action Plan and developing FY2016 plan. http://www.fda.gov/aboutfda/centersoffices/ucm392733.htm
• Target areas are specialization, training, work planning, compliance and enforcement, and imports
• We are aligned in many aspects and are fine tuning to further integrate:– Team Biologics – biological drugs and devices– Biologics Cadre – blood, plasma, 361 HCT/Ps
22
• Facilitating the importation and exportation of clinical trial materials for Ebola.
• Part of an intergovernmental working group providing communication channels between all relevant government components: CBP, HHS/BARDA, FDA, CDC, USDA/APHIS, DOT, FWS, DOC/BIS
23
Vision for CBER
24
CBER uses sound science and regulatory expertise to:
Protect and improve public and individual health in the US and, where feasible, globally
Facilitate development, approval of and access to safe and effective products and promising new technologies
Strengthen CBER as a preeminent regulatory organization for biologics
Cynthia Schnedar, J.D.Director, CDER Office of Compliance
December 9, 2015Washington, DC
Compliance Update
27
One Quality Voice• For Drugs
• For Patients
• For Industry
• For Healthcare Professionals
• For Healthcare Purchasers
Priorities
CDER reorganization
Program alignment
Implementing legislative authorities
Compliance and enforcement actions
Track & trace
Compounding28
Office of Manufacturing Quality (OMQ) Focus
• Current Good Manufacturing Practices• Mutual reliance / Increase in joint inspections
with international regulatory partners
• Global training
• Data Reliability
OMQ ActionsJanuary to October 2015
Import Alerts, 18
Untitled Letters, 5
Warning Letters, 16
January to October 2015
Import Alerts, 18
Untitled Letters, 5
Warning Letters, 16
CY2014 drug GMP Warning Letters
Manufacturer location
CY2014 drug GMP Warning Letters
Placed on Import Alert (#66-40)
Cited data reliability issue
Foreign 19 8 11
*Domestic 1 N/A 0
* Does not include Warning Letters issued to compounders
Office of Unapproved Drugs and Labeling Compliance (OUDLC)
Focus•Develops and implements policies and strategies to ensure compliance with new drug and labeling requirements of the FD&C Act•Directs inspections and coordinates compliance and enforcement actions regarding:
•Implements the compounding provisions of the Drug Quality and Security Act (DQSA) 32
Compounding Actions
33
• Since enactment of the DQSA on November 27, 2013, FDA has completed the following actions:– Conducted approximately 200 inspections of
compounders.– Issued a Form FDA 483 at the conclusion of almost
all of its inspections.– Issued approximately 60 warning letters to
compounders including one warning letter that addressed violations identified at four facilities.
– Issued to state boards of pharmacy approximately 20 letters referring findings from inspections of pharmacies that appeared to operate in accordance with section 503A of the Act.
Compounding Policy• Since enactment of the DQSA, to implement
the new law and clarify its policies regarding compounding and related activities, including repackaging, FDA has issued:– 12 draft guidances, 5 of which were finalized– A draft memorandum of understanding– A proposed rule
• FDA also held three meetings of the Pharmacy Compounding Advisory Committee.
FDA’s Compounding Website
• Keep up to date on developments at:http://www.fda.gov/Drugs/
•Site contains links to:• all policy documents including Guidances (final and
draft), • Form FDA 483s and Warning Letters issued, • a list of registered outsourcing facilities, and • questions and answers about what it does and does
not mean to be a registered outsourcing facility
Office of Drug Security, Integrity, and Response (ODSIR) Focus
• Title II - Product tracing (track and trace)
• Regulates internet pharmacies
• Operation Pangea• Counterfeit and foreign
approved drug actions• Indictments /
Prosecutions• Letters to doctors
• APEC Supply Chain Roadmap
• WHO spurious/falsely-labelled/falsified/counterfeit (SFFC) medicines
• Recalls
36
Major Reasons for Recalls FY 12-15*
2012 - Impurities/Degradation Products- GMP Deviations- Lack of Assurance of Sterility
2013 - Lack of Assurance of Sterility- Impurities/Degradation Products- Presence of Particulate Matter
2014 - Marketed without an Approved NDA/ANDA- Presence of Particulate Matter
- Lack of Assurance of Sterility
2015* - Lack of Assurance of Sterility- Presence of Particulate Matter- Impurities/Degradation Products
*=Quarter 4
• Focus– Enforces the following requirements
• BIMO (bioresearch monitoring)• Risk Evaluation and Mitigation Strategies
(REMS)• Post-market adverse drug event reporting• Post-marketing requirements (PMRs)
– International Collaboration
Office of Scientific Investigations (OSI) Activities
• Activities– Engage with UK & EU health authorities to
conduct GCP and bioequivalence inspections
– Collaborate with ICH to modernize clinical trials
– Develop enforcement standards for IRBs and RDRCs
Office of Scientific Investigations (OSI) Activities (cont’d)
FY2014 OSI Warning Letters & Disqualifications
11
3
1 1
5
2
Compliance CentralCenter for Devices and Radiological Health
CAPT Sean M. Boyd, MPH, USPHS
Acting DirectorOffice of Compliance
CDRH Office of Compliance
FDLI LEC 12/09/2015
Medical Device Quality System Data
• Increasing proportion of foreign inspections as foreign manufacturer inventory growing rapidly
• Piloting inspections in non-traditional situations including 510(k)s, de novos, post-approval studies.– Risk based approach– 19 inspections performed annually in FY14 and FY15
for Class II devices related to 510(k) and De Novo submissions
MDSAP
• Single regulatory audit of firm’s quality management system satisfies needs of multiple regulatory jurisdictions
• Substitute for FDA routine surveillance inspections– For-cause, follow-up, pre-approval, post-
approval inspections not affected
• Pilot through December 2016, implementation in 2017
FDLI LEC 12/09/2015
52
MDSAP• Many aspects of pilot promising, on-track
– 5 regulatory partners committed to the program (Australia Brazil, Canada, Japan, US)
– 6 third party auditing organizations authorized to conduct audits of medical device manufacturers
– 59 participating manufacturing sites as of December 1, 2015– Health Canada transitioning to MDSAP starting in January 2017
• Evaluating documents, policies and audit/assessment models and reports to validate Pilot Proof of Concept
• Accepting manufacturer and auditing organization feedback to improve MDSAP processes
53
54
Program Alignment• Establish commodity-based and vertically
integrated Regulatory Programs– Delayering/streamlining– Specialization– Training– Workplanning– Compliance and quality policy, enforcement and
engagement– Import operations– Lab optimization
FDLI LEC 12/09/2015
FDLI LEC 12/09/2015
What does this mean?
• Investigators, compliance officers and managers specialized by program
• Increased understanding of technology and manufacturing processes
• Development of team-based approaches and streamlined decision-making
• Shared strategic priorities & program goals• Work planning based on risk and global
• Collaborative interaction among device stakeholders to promote improvement in device quality through a variety of activities relating to quality of the organization, system, product and personnel.
• Both FDA and industry looking at what we need to do to align our approach on quality to the lessons learned from these collaborative activities.
FDLI LEC 12/09/2015
Collaboration
• Medical Device Innovation Consortium– Measures and Metrics– Quality maturity– Data analytics– Competency development
• Adapting industry and FDA practices to shift toward quality focus
FDLI LEC 12/09/2015
Data Sharing• Identifying new metrics and applications for
internal FDA data• Release of application programming interfaces
(API) to allow external use of FDAs public data– Adverse events– Device classification– PMA– Recalls– 510k– Registration and listing
https://open.fda.gov/index.html
MDIC CfQ Forum 12082015 61
Focus on Quality• Critical to Quality Technical Documents
– Lists quality indicators related to product features or manufacturing processes that are essential to the quality of a device
– May be specific to a particular submission, a specific device, or class of devices
– Used to link technical design or process related information to a traditional QSIT inspectional approach, but may be more broadly applied
FDLI LEC 12/09/2015
Example CtQ Indicator
Key characteristicKey characteristic
Impactof failureImpact
of failure
ControlControl
Reference to 820Reference to 820 Reference to QSITReference to QSITMDIC CfQ Forum 12082015 63
Critical to Quality DocumentsCtQ Information Document Who was involved?
Implantable devices with batteries CDRH, Battery Suppliers, OEMs